New York continues to be reeling from an epidemic tied to greater than 22,000 deaths and it continues to be observed how some distance other people shall be prepared to head. New York City has inched closer to restoring its reputation as a thriving, hectic metropolis, as the second phase of reopening begins in the city which experienced the deadliest […]Read more ›
Focusing on the social determinants of health The impact of COVID-19 is being felt most acutely by older patients whose health risks are compounded by multi-morbidity as well as compromised immune systems, decreased physiological reserve, frailty and sarcopenia. Data from the World Health Organization shows that more than 95% of COVID-19 deaths around the world have been among people over […]Read more ›
The fresh cluster in Beijing has raised fears of a resurgence of the virus in China, which had largely brought the disease under control over recent months.
Dozens of communities have been sealed off in the city to contain the spread, with residents told to avoid non-essential travel and schools closed.Read more ›
The United States lost another 568 people to the new coronavirus in the 24 hours leading up to 8:30 pm Saturday (0030 GMT Sunday), according a tally by Johns Hopkins University. It marked the 10th day in which the daily toll from the virus has been fewer than 1,000, even as the US remains the country hardest-hit by the pandemic with 119,654 deaths out of 2,251,205 official cases.Read more ›
Ghanaian health officials on Saturday said over 10,000 persons infected with the coronavirus have now recovered. The significant number of recoveries means the country now has only a little over 3,000 active cases of the virus out of almost 14,000 infections. 85 persons have so far been confirmed to have died from the virus, according […]
The post Covid-19: Ghana records significant recovery numbers appeared first on Africa Feeds.
In it, packed with dry ice, were several tiny vials. Each one held a few drops of “seed stock,” a starter kit for the production of a potential vaccine for the novel coronavirus.
The company’s job was to turn a few droplets into an amount large enough for 13,000 people — a sufficient quantity to perform large-scale trials unfolding on several continents.
“We could really feel the pressure,” said Francesco Calvaruso, the production manager of Advent, which needed two months to grow, filter and purify a trial vaccine known as AZD1222.